Tocqueville Asset Management L.P. Buys New Position in Immix Biopharma, Inc. $IMMX

Tocqueville Asset Management L.P. purchased a new position in shares of Immix Biopharma, Inc. (NASDAQ:IMMX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 88,550 shares of the company’s stock, valued at approximately $913,000. Tocqueville Asset Management L.P. owned 0.16% of Immix Biopharma at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Janus Henderson Group PLC lifted its holdings in Immix Biopharma by 22.5% during the 1st quarter. Janus Henderson Group PLC now owns 4,802,002 shares of the company’s stock worth $43,698,000 after buying an additional 880,434 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Immix Biopharma in the second quarter valued at $30,827,000. Eventide Asset Management LLC acquired a new stake in Immix Biopharma in the 4th quarter valued at about $13,331,000. Marshall Wace LLP boosted its stake in shares of Immix Biopharma by 3,495.4% in the 4th quarter. Marshall Wace LLP now owns 1,978,743 shares of the company’s stock valued at $10,349,000 after buying an additional 1,923,708 shares during the period. Finally, Millennium Management LLC acquired a new position in shares of Immix Biopharma during the fourth quarter worth about $8,681,000. Institutional investors and hedge funds own 11.26% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on IMMX shares. Bank of America started coverage on shares of Immix Biopharma in a report on Thursday, June 18th. They issued a “buy” rating and a $27.00 target price on the stock. Citigroup reaffirmed a “market outperform” rating on shares of Immix Biopharma in a research report on Friday, August 14th. HC Wainwright increased their target price on Immix Biopharma from $20.00 to $25.00 and gave the company a “buy” rating in a report on Monday, August 10th. Lifesci Capital started coverage on Immix Biopharma in a report on Wednesday, June 17th. They set an “outperform” rating and a $19.00 price target for the company. Finally, Morgan Stanley lowered their price objective on Immix Biopharma from $20.00 to $19.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Immix Biopharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.29.

Immix Biopharma Stock Down 0.2%

NASDAQ:IMMX opened at $13.16 on Friday. The stock’s 50 day moving average price is $9.98 and its 200 day moving average price is $9.24. The company has a market capitalization of $941.47 million, a PE ratio of -14.95 and a beta of 0.11. Immix Biopharma, Inc. has a 52-week low of $1.94 and a 52-week high of $13.20.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). As a group, sell-side analysts anticipate that Immix Biopharma, Inc. will post -0.74 EPS for the current fiscal year.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.